On 2 November 2026 Washington State University reported that Regents Professor Jon Oatley has a two-year, $274,849 grant from the Washington Research Foundation to take Alphatide, a peptide-based male contraceptive developed in his lab, through its final preclinical studies. This is our summary of the report, followed by the MedBridge Global team’s view. Read the full story on WSU Insider.

What Alphatide does

Alphatide is designed to interrupt sperm development rather than act on hormones. It targets the interaction between two proteins, ARRDC5 and TEX38, which earlier work by Oatley’s team found only in male reproductive tissue and which are essential for fertility. In Oatley’s words, “What we’re targeting is really specific to sperm development.”

The team used computational modelling to screen FDA-approved compounds for the ones most likely to disrupt that interaction. One peptide stood out, and the team then modelled and evaluated more than 2,000 variations of it to improve stability, solubility and effectiveness. The result is Alphatide. Like other peptides, it is broken down by the body into amino acids after use, which the report notes may reduce the risk of unintended side effects.

Where the research stands

  • The work is preclinical. In mice, the contraceptive effect has been reversible and has not appeared to cause adverse health effects. No human data has been reported.
  • The new grant funds the studies the FDA needs before human testing can begin: where the peptide goes in the body, how long it stays active and how quickly it is cleared.
  • Oatley expects the team can be ready to apply for human clinical trials within about three years. No start date has been set.
  • WSU has filed a provisional patent and is working with a start-up, not named in the report, on the commercial potential in humans.

Why it matters

Oatley cites a World Health Organization estimate that roughly half of pregnancies worldwide are unintended, and notes that men have few options beyond condoms and vasectomy. A reversible, non-hormonal option would fill a gap that decades of hormonal male contraceptive research has not closed. He also says that, to his knowledge, no one else is working on peptides for male contraception. Because the target proteins appear in the testes of virtually every male species, the same approach could one day offer an alternative to surgical castration in livestock and companion animals.

The MedBridge Global team’s view

This is the path we want to see peptides take: a precise biological target, a clear mechanism, and a sequence of preclinical and then clinical studies before any patient receives it. It is a useful contrast with the peptides currently sold online on the strength of animal data alone. It also shows that, alongside insulin and the GLP-1 drugs, peptides are being designed for problems well beyond metabolism and recovery.

For clinicians, the takeaway today is patience. Alphatide has been tested only in mice, and it is years from any prescription pad. Patients may well ask about it after headlines like this, and the honest answer is that it is promising but unproven, with human trials still to come. We will follow its progress toward an FDA application. For the regulatory side of peptides that are already prescribed, read our summary of HHS opening compounding access to six wellness peptides. Our Peptide Master Certification teaches prescribers how to read peptide evidence, from mechanism and animal data to clinical trials.

Sources